PHOENIX, Oct. 21, 2014 /PRNewswire/ -- Global Cancer Diagnostics Inc. today announced the availability of The Lung Cancer Test beginning, October 20, 2014. All required Clinical Validation studies are complete with excellent results. The Test detects the presence of the required biomarkers that aid in the early detection of lung cancer. Global Cancer Diagnostics (GCDx) plans to offer this new test on a nationwide basis, starting with Arizona and several other states.
Logo - http://photos.prnewswire.com/prnh/20141021/153340LOGO
Lung cancer is the most fatal of cancers taking an estimated 158,000 lives annually in the U.S. alone. Smoking contributes from 80 to 90% of lung cancer deaths. Lung cancer is the leading cause of cancer death among both men and women only about 15% of those diagnosed will live beyond 5 years. The 5 year survival rate rises to 53.3 when the cancer is found in stages 1 and 2. But only 15% of cases are diagnosed at an early stage. The CDC estimated in 2010 that there were 43.5 million smokers in the U.S. and that the number of former smokers exceeded the number of current smokers.
Clinical Studies have demonstrated that The Lung Cancer Test successfully detected the presence of certain biomarkers for Stages 1 and Stage 2 lung cancer with a high degree of accuracy. “A screening test for early stage lung cancer is a goal long sought in the industry,” shared Global Cancer CEO William Gartner. GCDx intends to introduce The Lung Cancer Test from its CLIA Laboratory on October 20, 2014. The test can be purchased through the Company’s website at www.GlobalCancerDx.com for $99.00 plus s&h. The test can be ordered with a doctor’s order in all states or directly in the 26 states noted on their website.
The Lung Cancer Test is intended for use in the high-risk lung cancer patient population which includes current and former smokers over the age of 50.
“We believe this test will change the way that lung cancer is detected and can potentially save thousands of lives,” said Gartner.
About Global Cancer Diagnostics Inc.
Global Cancer Diagnostics is a privately owned biotechnology company with an in-house medical diagnostic laboratory. The Company is located in Tempe, AZ. The GCDx provides the scientific and operating management resources to advance the introduction of this novel diagnostic technology into the domestic and global marketplace. For more information, visit the company’s Web site at www.GlobalCancerDx.com
INFORMATION:
Global Cancer Diagnostics Inc.
602.908-9604
William Gartner, President & CEO
Email
Don Roberton, VP & COO
Email
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arizona-company-launches-lung-cancer-test-for-99-538062751.html
SOURCE Global Cancer Diagnostics Inc.
Help employers find you! Check out all the jobs and post your resume.
